keyword
https://read.qxmd.com/read/36261374/a-hepatitis-b-virus-reactivation-case-potentially-triggered-by-the-onset-of-diffuse-large-b-cell-lymphoma
#21
JOURNAL ARTICLE
Kentaro Sato, Hidemichi Imamura, Yu Watahiki, Hiromasa Hazama, Takeaki Hashimoto, Shinji Mukae, Hiromasa Ohhira
An 81-year-old man underwent rituximab-containing chemotherapy for chronic lymphocytic leukemia (CLL). Thirteen years after his last chemotherapy, he was diagnosed with hepatitis B virus (HBV) reactivation. He was then treated with entecavir, and improvement was seen in his liver injury. He developed diffuse large B cell lymphoma (DLBCL) after improvement in his hepatitis. Despite chemotherapy, he contracted the coronavirus disease 2019 (COVID-19) and died of COVID-19. We suspect that HBV reactivation was triggered by DLBCL...
October 19, 2022: Internal Medicine
https://read.qxmd.com/read/36016402/hepatitis-b-surface-antibody-anti-hbs-kinetics-during-rituximab-chemotherapy-and-performance-of-hepatitis-b-vaccine-before-immunosuppression-two-prospective-studies
#22
JOURNAL ARTICLE
João Marcello de Araujo-Neto, Gabriela Sousa Guimarães, Flavia Ferreira Fernandes, Marcelo A Soares
Rituximab promotes strong immunosuppression leading to a high risk of hepatitis B reactivation (HBV-R) and chronic infection. Current recommendations on HBV-R prevention are expensive and poorly individualized. In resolved hepatitis B patients, previous studies suggest that anti-HBs titers before immunosuppression can predict HBV-R risk. However, guidelines claim that additional data are necessary before recommending spare drug prophylaxis in patients with high anti-HBs titers. On the other hand, in patients with no previous contact with HBV, guidelines recommend vaccine before immunosuppression despite minimal evidence available...
August 15, 2022: Viruses
https://read.qxmd.com/read/36001617/prevalence-and-management-of-chronic-hepatitis-b-in-pemphigus-and-pemphigoid-patients-new-evidence-for-the-safety-of-rituximab
#23
JOURNAL ARTICLE
Zeinab Aryanian, Amir Tahooneban, Kamran Balighi, Maryam Daneshpazhooh, Hamidreza Mahmoudi, Tahereh Souri, Zeinab Mohseniafshar, Soheil Tavakolpour, Parvaneh Hatami
BACKGROUND: Although the treatments of pemphigus and pemphigoid patients have tended toward safer options, patients with chronic infections seem to be still at the risk of infection reactivation when they are exposed to any of immunosuppressive treatments. AIM: To evaluate the prevalence of chronic HBV as well as its risk factors and management approach in patients with pemphigus and pemphigoid. METHODS: A retrospective study on 1646 registered pemphigus and pemphigoid patients was conducted between Jan 2017 to Feb 2019...
August 24, 2022: Dermatologic Therapy
https://read.qxmd.com/read/35990784/hepatotoxicity-during-legacy-cancer-chemotherapy-in-patients-infected-with-hepatitis-c-virus-a-retrospective-cohort-study
#24
JOURNAL ARTICLE
Jean-Luc Szpakowski, Lue-Yen Tucker, David M Baer, Mary Pat Pauly
BACKGROUND: The rates and causes of significant hepatotoxicity with cancer chemotherapy (CCT) in patients infected with hepatitis C virus (HCV) are incompletely characterized. METHODS: We compared rates of grade 3 or 4 hepatotoxicity, defined as elevated transaminases, during CCT in patients who are mono-infected with HCV compared with rates in controls matched on demographics, diagnosis, and rituximab use. We excluded patients with hepatobiliary cancers, hepatitis B virus or human immunodeficiency virus infection...
2022: Canadian liver journal
https://read.qxmd.com/read/35864918/efficacy-and-safety-of-rituximab-as-second-line-therapy-in-immune-thrombocytopenic-purpura-based-on-ethnicity-a-descriptive-study-among-the-arabic-population
#25
JOURNAL ARTICLE
Fateen Ata, Zohaib Yousaf, Fathima Z Zahir, Anas Mohamed Babiker, Amer Ali Farooqi, Mousa Ahmad Al Hiyari, Adel Issam Al Bozom, Ahmed Hatim Mohamed, Abdulqadir J Nashwan, Mohamed A Yassin
BACKGROUND: Rituximab is used as second-line therapy in patients with immune thrombocytopenic purpura (ITP) who do not respond to first-line management. The response rate for Rituximab is variable in different populations ranging from 30% to 90%. The adverse effects of rituximab in patients with ITP range from infusion site reactions to the reactivation of hepatitis B virus and progressive multifocal leukoencephalopathy and interpopulation variation. METHODS: We conducted a single-center, retrospective study in Qatar's National Center for Cancer Care & Research...
2022: Qatar Medical Journal
https://read.qxmd.com/read/35712098/long-term-safety-of-rituximab-in-dlbcl-patients-with-hepatitis-b-related-cirrhosis-a-retrospective-case-series
#26
Zaiwei Song, Yi Ma, Dan Jiang, Rongsheng Zhao, Fei Dong
Objective: Chemotherapy regimens containing rituximab (RTX) have been extensively used to treat diffuse large B cell lymphoma (DLBCL). However, data looking at long-term safety of DLBCL patients with hepatitis B-related cirrhosis are still lacking. This study aims to report the safety and outcomes of RTX administration in DLBCL patients with hepatitis B-related cirrhosis. Methods: A retrospective case series was designed and implemented, using data from January 1, 2011 to December 31, 2020...
2022: Frontiers in Medicine
https://read.qxmd.com/read/35070716/late-hepatitis-b-reactivation-after-treatment-with-rituximab
#27
Sara Lacerda Pereira, Raquel Duro, António Sarmento
There is a large reservoir of individuals with past hepatitis B virus (HBV) infection that are in risk for HBV reactivation when immunosuppressed. On the setting of hematologic malignancy, the malignancy itself and currently used treatments, especially anti-CD20 agents, have risk of HBV reactivation. Antiviral prophylaxis is recommended by some international societies. We present a case of HBV reactivation more than 12 months after stopping rituximab containing treatment and 6 months of antiviral prophylaxis with entecavir, in a patient with HBV functional cure...
2022: IDCases
https://read.qxmd.com/read/34854079/significance-of-anti-hbc-serological-status-in-primary-immune-thrombocytopenia
#28
JOURNAL ARTICLE
Lingjun Wang, Lizhen Li, Chaoyang Li, Yu Hou, Miao Xu, Yafei Yu, Xiaofei Ni, Ruting Wang, Haoyi Wang, Lin Wang, Jun Peng, Ming Hou
The association of previous hepatitis B virus (HBV) exposure [hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (anti-HBc/HBcAb) positive] with disease severity and decision on treatment option in primary immune thrombocytopenia (ITP) patients remains unclear. Data from 725 patients diagnosed with ITP were analyzed to elucidate the association between anti-HBc serological status and disease severity. Data from a published prospective study [high-dose dexamethasone (HD-DXM), HD-DXM plus recombinant human thrombopoietin, NCT01734044] and two retrospective studies (standard-dose and low-dose rituximab) were rearranged to evaluate the impact of anti-HBc serological status on the response and outcome to ITP-specific treatments and the risk of HBV reactivation related to these treatments...
February 2022: British Journal of Haematology
https://read.qxmd.com/read/34759100/-hepatits-b-virus-reactivation-in-patients-receiving-immunosuppressive-therapy-or-chemotherapy-and-effective-prophylactic-management-a-prospective-observational-study-in-a-hospital-over-an-8-year-period
#29
JOURNAL ARTICLE
Kazuo Notsumata, Hiroki Matsukawa, Genta Yamakawa, Yoshimoto Nomura, Katsuyoshi Nomura, Teruyuki Ueda, Taku Sanada, Hiroyuki Watanabe, Daishu Toya
We investigated the development of hepatits B virus (HBV) reactivation in patients receiving immunosuppressive therapy or chemotherapy at our hospital for 8 years. Using the automatic checking system for HBV reactivation coded using medical information that has been in operation in our hospital since October 2012, we prospectively observed the occurrence status of HBV reactivation in immunosuppressive/chemotherapy cases for 8 years. HBV reactivation occurred in 31 of 1516 patients with HBV infection. It occurred annually between 1 and 7 cases in multiple clinical departments, and in 8 of 59 patients treated with rituximab, 10 of 653 patients treated with antineoplastic agents, 10 of 399 patients treated with steroids, and 3 of 212 patients treated with direct-acting antivirals...
2021: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://read.qxmd.com/read/34649275/worse-outcome-and-distinct-mutational-pattern-in-follicular-lymphoma-with-anti-hbc-positivity
#30
JOURNAL ARTICLE
Concepción Fernández-Rodríguez, Juan José Rodríguez-Sevilla, Lierni Fernández-Ibarrondo, Blanca Sánchez-González, Joan Gibert, Leire Bento, Juan Fernando García, Juan Manuel Sancho, Ramón Diez-Feijóo, Laura Camacho, Montserrat García-Retortillo, Eva Gimeno, Luis Colomo, Antonio Gutiérrez, Beatriz Bellosillo, Antonio Salar
Epidemiological studies have demonstrated the association between hepatitis B virus (HBV) infection and B-cell non-Hodgkin lymphoma (NHL), mainly for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). We studied a cohort of 121 patients with FL for HBV infection status, clinical features, and gene mutational profile. Anti-HBc was detectable in 16 patients (13.2%), although all had undetectable HBV DNA. Anti-HBcore+ (anti-HBc+) cases presented with older age at diagnosis than anti-HBc- cases (68...
January 11, 2022: Blood Advances
https://read.qxmd.com/read/34569486/ibrutinib-in-advanced-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-lower-risk-of-hepatitis-b-virus-reactivation
#31
JOURNAL ARTICLE
Shenmiao Yang, Rong Zhu, Nan Li, Yu Feng, Rui Zuo, Robert Peter Gale, Xiaojun Huang
INTRODUCTION: Therapy of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with drugs such as ibrutinib and rituximab is often associated with immune suppression, opportunistic infections, and reactivation of virus infections such as hepatitis B virus (HBV). This risk is especially important in geographical regions like Asia where many potential therapy recipients have HBV infection. Also, whether safety and efficacy of ibrutinib in Asians and Europeans with advanced CLL/SLL are similar is unknown...
September 20, 2021: Acta Haematologica
https://read.qxmd.com/read/34476737/long-term-safety-of-rituximab-in-rheumatic-patients-with-previously-resolved-hepatitis-b-virus-infection
#32
JOURNAL ARTICLE
Michele Barone, Vincenzo Venerito, Rosa Paolillo, Giacomo Emmi, Marco Fornaro, Fabio Cacciapaglia, Luca Cantarini, Alfredo Di Leo, Florenzo Iannone, Giuseppe Lopalco
Conflicting results can be found in the literature on the frequency of hepatitis B virus (HBV) reactivation (HBVr) on rituximab (RTX) in rheumatic patients with previously resolved HBV (prHBV) infection. Here, we report the frequency of HBVr in a large historical cohort of caucasian rheumatic patients with prHBV receiving RTX. Registry data of rheumatic patients treated with RTX were retrospectively analysed. Demographic and clinical characteristics including evaluation of anti-HCV and HBV markers, annual HBV-DNA determination and aminotransferase levels assessed every three months, were recorded...
March 2022: Internal and Emergency Medicine
https://read.qxmd.com/read/34368296/prevention-of-hepatitis-b-reactivation-in-patients-requiring-chemotherapy-and-immunosuppressive-therapy
#33
REVIEW
Chih-An Shih, Wen-Chi Chen
Hepatitis B virus (HBV) reactivation can lead to severe acute hepatic failure and death in patients with HBV infection. HBV reactivation (HBVr) most commonly develops in patients undergoing cancer chemotherapy, especially B cell-depleting agent therapy such as rituximab and ofatumumab for hematological or solid organ malignancies and that receiving hematopoietic stem cell transplantation without antiviral prophylaxis. In addition, the potential consequences of HBVr is particularly a concern when patients are exposed to either immunosuppressive or biologic therapies for the management of rheumatologic diseases, inflammatory bowel disease and dermatologic diseases...
July 26, 2021: World Journal of Clinical Cases
https://read.qxmd.com/read/34331726/evaluation-of-hepatitis-b-screening-and-reactivation-in-patients-receiving-rituximab-containing-chemotherapy-a-single-centre-study
#34
JOURNAL ARTICLE
Ilkay Bozkurt, Hatun Ozturk Cerik, Seher Kir, Muge Ustaoglu, Mehmet Turgut, Saban Esen
AIMS: Hepatitis B virus (HBV) infection is a worldwide distributing viral disease. Hepatitis caused by HBV reactivation may progress to chronic illness and associated with increased risk of hepatic failure and hepatocellular cancer. Rituximab (RTX) is an immunosuppressive agent, is particularly used in the treatment of non-Hodgkin's Lymphoma. Patients have significant risk for HBV reactivation following chemotherapy with a RTX-containing regimen. This study aimed to determine the HBV screening manner and reactivation rates in patients with haematological neoplasm following chemotherapy including Rituximab...
July 31, 2021: International Journal of Clinical Practice
https://read.qxmd.com/read/34323157/role-of-quantitative-hepatitis-b-surface-antibodies-in-preventing-hepatitis-b-virus-related-hepatitis-in-patients-treated-with-rituximab
#35
JOURNAL ARTICLE
Sung-Nan Pei, Yan-Fang Liu, Chin-Yuan Kuo, Ming-Chung Wang, Ming-Chun Ma, Chun-Kai Liao, Hwee-Yeong Ng, Chien-Hung Chen
Hepatitis B virus (HBV) reactivation is a well-known complication after rituximab-based chemotherapy in patients with B cell lymphoma (BCL) who have resolved HBV infection. This retrospective cohort study used electronic medical records from the Kaohsiung Chang Gung Memorial Hospital. There were 128 patients with BCL and resolved HBV infection treated with 1st-line rituximab-containing therapy from 2008 to 2013. No patient received antiviral prophylaxis. Patients with high pretreatment hepatitis B surface antibody (anti-HBs titer ≥100 mIU/mL), had significantly less HBV reactivation (2...
July 29, 2021: Leukemia & Lymphoma
https://read.qxmd.com/read/34277431/hbv-reactivation-during-the-treatment-of-non-hodgkin-lymphoma-and-management-strategies
#36
REVIEW
Xing Cao, Yafei Wang, Panyun Li, Wei Huang, Xiaojuan Lu, Hongda Lu
Hepatitis B virus reactivation (HBV-R), which can lead to HBV-related morbidity and mortality, is a common and well-known complication that occurs during the treatment of non-Hodgkin lymphoma (NHL) patients with current or past exposure to HBV infection. HBV-R is thought to be closely associated with chemotherapeutic or immunosuppressive therapies. However, immunosuppressive agents such as anti-CD20 antibodies (e.g., rituximab and ofatumumab), glucocorticoids, and hematopoietic stem cell transplantation (HSCT) administered to NHL patients during treatment can cause deep immunodepression and place them at high risk of HBV-R...
2021: Frontiers in Oncology
https://read.qxmd.com/read/34269903/long-term-safety-of-rituximab-risks-of-viral-and-opportunistic-infections
#37
REVIEW
Cara D Varley, Kevin L Winthrop
PURPOSE OF REVIEW: We reviewed the current data on infections associated with rituximab use published over the last 5 years. RECENT FINDINGS: New literature was available on rates of serious infections, Hepatitis B reactivation and screening, and infection with Severe Acute Respiratory Syndrome Coronavirus 2. Rates of infection varied by study and population, however, higher risk of infection in patients with underlying rheumatologic diseases was seen in those who required a therapy switch, had a smoking history, and those undergoing retreatment who had a serious infection with their first course of therapy...
July 16, 2021: Current Rheumatology Reports
https://read.qxmd.com/read/34244190/liver-failure-from-delayed-hepatitis-b-reactivation-in-anti-hbc-positive-patient-following-rituximab-for-b-cell-lymphoma
#38
REVIEW
Branko Borojevic, Ayushi Chauhan, Scott Patterson
A 93-year-old man was admitted with 1 week of frank jaundice and abdominal pain. His medical history included diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, hydroxydaunomycin, oncovin and prednisolone (R-CHOP) chemotherapy 10 months prior. His investigations revealed marked hyperbilirubinemia with a total bilirubin of 355 μmol/L, along with a 17-fold elevation in alanine transaminase and impaired hepatic synthetic function. He tested hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (HBsAb) negative, hepatitis B core antibody (HBcAb) positive and had elevated hepatitis B virus DNA level at 13 691 IU/L...
July 9, 2021: BMJ Case Reports
https://read.qxmd.com/read/34187776/abatacept-is-second-to-rituximab-at-risk-of-hbsag-reverse-seroconversion-in-patients-with-rheumatic-disease
#39
JOURNAL ARTICLE
Ming-Han Chen, I-Cheng Lee, Ming-Huang Chen, Ming-Chih Hou, Chang-Youh Tsai, Yi-Hsiang Huang
BACKGROUND: Hepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence and risk factors need to be delineated. METHODS: From 2003 to 2019, 1937 patients with RA with available HBsAg and antibody to hepatitis B virus (HBV) core antigen data were retrospectively reviewed, and 489 patients with RHB undergoing bDMARDs treatment were identified...
November 2021: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/34160359/what-is-the-risk-of-reactivation-in-patients-with-resolved-and-past-hbv-infection-during-immunosuppressive-therapy-if-hbv-dna-negative-before-treatment
#40
JOURNAL ARTICLE
Salih Tokmak, Yüksel Gümürdülü, Didem A Taş, İbrahim O Kara, Ahmet B Güzel
BACKGROUND: Reactivation of Hepatitis B (HBVr) related to immunosuppressive drug therapy (ISDT) in patients with resolved and past infection is a challenging entity. The number of prospective long-term studies is limited. METHODS: Two groups of patients with resolved and past HBV infection were analyzed prospectively. The patients were further categorized as 266 patients receiving ISDT (group 1) and 246 patients receiving antineoplastic therapy (group 2). RESULTS: We did not detect any cases of HBVr among 108 patients receiving rituximab (71 of which were anti-HBc positive only), 111 patients receiving tumor necrosis factor inhibitors (66 of which were anti-HBc positive only), and 42 patients receiving high-dose glucocorticoids for more than 4 weeks (24 of which were anti-HBc positive only) during a mean follow-up time of more than 24 months...
March 2021: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
keyword
keyword
110035
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.